EFPIA Unveils Nathalie Moll as New Director General
The EFPIA has revealed the appointment of Nathalie Moll as its new director general.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has revealed the appointment of Nathalie Moll as its new director general. Currently secretary general of the European Association for Bioindustries (EuropaBio), she will join EFPIA in April 2017.
Commenting on the appointment, Joe Jimenez, President of EFPIA, said “Nathalie has an excellent track record of leadership and engagement across the life science sector. We are confident she is the right person to lead EFPIA, working with stakeholders to address the challenges faced by healthcare systems in Europe.”
Moll became secretary general of EuropaBio. Moll, currently EuropaBio’s director for agricultural biotechnology in April 2010, replacing Willy De Greef.
“I am delighted to be joining EFPIA at a time when pharmaceutical innovation is having such a dramatic effect on the lives of patients across Europe,” she said. “I look forward to working with EFPIA Members, staff and the wider research, healthcare and policy community to foster an environment that supports continued innovation and drives better outcomes for patients.”
Eric Cornut will continue to lead EFPIA as interim director general until Moll joins the organisation in April.
Philip Ward is the European Editor for Applied Clinical Trials
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
